All Pharma News
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
GLOBENEWSWIRE
22 Apr 2024
Share Share
ORYZON Announces FDA Clearance of Iadademstat for SCLC

ORYZON Announces FDA Clearance of Iadademstat for SCLC
GLOBENEWSWIRE
08 Apr 2024
Share Share
ORYZON to Provide Corporate Progress Updates at Several Events in April

ORYZON to Provide Corporate Progress Updates at Several Events in April
GLOBENEWSWIRE
05 Apr 2024
Share Share
ORYZON Reports Financial Results for Quarter Ended December 31, 2023

ORYZON Reports Financial Results for Quarter Ended December 31, 2023
GLOBENEWSWIRE
26 Feb 2024
Share Share
ORYZON to Provide Corporate Progress Updates at Several Events in February-March

ORYZON to Provide Corporate Progress Updates at Several Events in February-March
GLOBENEWSWIRE
05 Feb 2024
Share Share
ORYZON to Host KOL Event on PIIb PORTICO Topline Study Results of Vafidemstat

ORYZON to Host KOL Event on PIIb PORTICO Topline Study Results of Vafidemstat
GLOBENEWSWIRE
19 Jan 2024
Share Share
Oryzon med fails to improve borderline personality disorder

Oryzon med fails to improve borderline personality disorder
Annalee Armstrong FIERCE BIOTECH
07 Jan 2024
Share Share
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat
GLOBENEWSWIRE
05 Jan 2024
Share Share
ORYZON to Provide Corporate Progress Updates at Several Events in January

ORYZON to Provide Corporate Progress Updates at Several Events in January
GLOBENEWSWIRE
03 Jan 2024
Share Share
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.

ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
GLOBENEWSWIRE
04 Dec 2023
Share Share